PROGRESS AND CHALLENGES ON HPV VACCINATION AND SCREENING IN DEVELOPED AND DEVELOPED COUNTRIES

PROGRAM

Thursday, March, 22nd, 2012

PLENARY SESSION I: EPIDEMIOLOGY, Virology, Immunology AND SCREENING

14:00  Introduction and presentations
F.X. Bosch and organizing group
14:15  Project status, deliverables & publications, dissemination plan, editorial aspects
F.X. Bosch, Catalan Institute of Oncology and WHO/ICO information center on HPV and cancer
14:50  The spectrum of HPV induced cancer: updating the discussion causality
F.X. Bosch, Catalan Institute of Oncology and WHO/ICO information center on HPV and cancer
15:10  Burden of HPV infections and related diseases worldwide
David Forman, International Agency for Research Cancer, Lyon, France
15:30  HPV and ano-genital cancer natural history in women and men
Barbara Moscicki, University of California, San Francisco, USA
15:50  HPV and head and neck cancers. Recurrent respiratory Papillomatosis
Maura Gillison, Ohio State Comprehensive Cancer Center, National Cancer Institute, USA
16:10  Mechanism of carcinogenesis. Pathology models
John Doorbar, National Institute for Medical Research, London, UK
17:00  Therapies against HPV
Peter Stern, Paterson Institute for Cancer Research, University of Manchester, UK
17:20  Immune response. Natural and vaccine-induced
Margaret Stanley, University of Cambridge, UK
17:40  Cervical cancer and other clinical indications
Marc Arbyn, Scientific Institute of Public Health, Brussels, Belgium
18:00  New technologies and procedures for cervical cancer screening
Jack Curick, Wolfson Institute of Preventive Medicine, Queen Mary University of London, UK
18:20  Introduction on HPV DNA screening in the world: 15 years of experience
F.X. Bosch. Philip Castle, American Society for Medical Pathology, Washington, USA

CO-ORGANIZERS:

Generalitat de Catalunya
Departament de Salut
ICO
Institut Català d’Oncologia
PROGRESS AND CHALLENGES ON HPV VACCINATION AND SCREENING IN DEVELOPED AND DEVELOPING COUNTRIES

PROGRAM

HOTEL MELIÀ SITGES. SITGES (BARCELONA)

Friday, March, 23rd, 2012

PLENARY SESSION II: HPV VACCINES, COST-EFFECTIVENESS SPECIAL GROUPS AND FUTURE RESEARCH

9:00  Prophylactic HPV vaccines: Completion of Phase III HPV trials
      John Sciller, National Cancer Institute, National Institute of Health, Bethesda, USA

9:30  HPV vaccine introduction: the first 5 years
      Laura Markowitz, Centers for Disease Control Prevention, Atlanta, USA

10:15 Modeling preventive strategies
      Karen Canfell, Cancer Council NSW, Woolloomooloo, Australia

10:45 HPV, HIV and immunosuppression
      Lynette Denny, University of Cape Town, South Africa

11:15 Prospects for research, Unanswered questions
      Laura Markowitz, Centers for Disease Control Prevention, Atlanta, USA

WORKING PARALLEL SESSION 1: CENTRAL-EASTERN EUROPE AND CENTRAL ASIA REPORT

13:30 Burden of HPV infections and related diseases
      Freddy Bray, International Agency for Research on Cancer, Lyon, France

14:15 Cervical cancer screening practices and current status of HPV vaccination implementation in Russia, Central Asia, Caucasus regions and western former soviet countries
      Svetlana Rogovskaya, Russian Medical Academy of Postdiploma Education, Moscow, Russia

15:15 Cervical cancer screening practices and current status of HPV vaccination implementation in de Central and European Europe
      Mario Poljak, Lab for Molecular Microbiology and Slovenian HIV/AIDS Center, Slovenia

16:00 Modeling strategies for cervical cancer prevention in EER
      Hans Berkhof, VU University Medical Center, Amsterdam, The Netherlands

16:45 Summary, review and discussion of the session
      Chair: Mario Poljak

CO-ORGANIZERS:
PROGRESS AND CHALLENGES ON HPV VACCINATION AND SCREENING IN DEVELOPED AND DEVELOPING COUNTRIES

PROGRAM

HOTEL MELIÀ SITGES. SITGES (BARCELONA)

Friday, March, 23rd, 2012

WORKING PARALLEL SESSION 2: EXTENDED MIDDLE EASTERN-NORTHERN AFRICA REPORT

13:30 Burden of HPV infections and related diseases
   Laia Bruni, Catalan Institute of Oncology

14:15 Changing trends in sexuality and sexual health in the MENA region: implication on the prevalence of HPV and other STIs
   Faysal El-Kack, American University of Beirut, Beirut, Lebanon

14:30 Screening practices: current status
   Helene Sancho Garnier, Montpellier University, Montpellier, France

15:15 HPV vaccination and determinants of acceptability of HPV vaccines
   Muhieddine Seoud, American University of Beirut, Beirut, Lebanon

16:00 Mathematical Models of Cervical Cancer Prevention in the Middle East and Northern Africa
   Jane Kim, Harvard School of Public Health, Boston, USA

16:45 Summary, review and discussion of the session
   Chair: Muhieddine Seoud

WORKING PARALLEL SESSION 3: SUB SAHARIAN AFRICA REPORT

13:30 Burden of HPV infections and related diseases
   Groesbeck Parham, Center Infectious Disease Research in Zambia, Lusaka, Zambia

14:15 Infrastructure requirements for vaccination and screening
   Lynette Denny, University of Cape Town, Cape Town, South Africa

15:15 On going trials and projects in prevention
   Peter Adefuye, Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria

16:00 Mathematical Models of Cervical Cancer Prevention in Sub-Saharan Africa
   Jane Kim, Harvard School of Public Health, Boston, USA

16:45 Summary, review and discussion of the session
   Chair: Lynette Denny

CO-ORGANIZERS:
PROGRESS AND CHALLENGES ON HPV VACCINATION AND SCREENING IN DEVELOPED AND DEVELOPING COUNTRIES

PROGRAM

HOTEL MELIÀ SITGES. SITGES (BARCELONA)

Friday, March, 23rd, 2012

WORKING PARALLEL SESSION 4: ISRAEL REPORT

13:30  Burden of HPV infections and related diseases
       M. Bar-Chana, Israel

14:15  Screening practices and current infrastructure
       E. Sjchechter, Israel

15:15  Economical modeling
       G Ginsberg, Israel

16:00  Determinants of acceptability of HPV vaccination
       W. Fisher, Israel

16:45  Summary, review and discussion of the session
       Chair: J. Bornstein

CO-ORGANIZERS:

Generalitat de Catalunya
Departament de Salut
ICO
Institut Català d’Oncologia
PROGRESS AND CHALLENGES ON HPV VACCINATION AND SCREENING IN DEVELOPED AND DEVELOPING COUNTRIES

PROGRAM

Saturday, March, 24th, 2012

PLENARY SESSION III: PUBLIC HEALTH ISSUES AND RECOMMENDATIONS. TOWARDS CERVICAL CANCER ERADICATION

9:00 Recommendations for HPV related cancer prevention in Eastern Europe
  Mario Poljak, Lab for Molecular Microbiology and Slovenian HIV/AIDS Center, Slovenia

9:45 Recommendations for HPV related cancer prevention in MENA region
  Muhieddine Seoud, American University of Beirut, Beirut, Lebanon

10:45 Recommendations for HPV related cancer prevention in Sub Saharan Africa
  Lynette Denny, University of Cape Town, South Africa

11:30 Recommendations for HPV related cancer prevention in Israel
  J. Bornstein

13:30 Translating scientific evidence to public health programs in developing countries
  Marc Stebben, Institute National de Santé Publique du Québec, Canada

14:00 Placing cervical cancer in the public health agenda, accelerating the arrival on HPV vaccines and screening to developing countries
  Mark Kane, Children’s Vaccine Program at PATH, Mercer Island, Washington, USA

14:30 Towards cervical cancer eradication
  F.X. Bosch, Catalan Institute of Oncology and WHO/ICO information center on HPV and cancer

15:15 Closing remarks, conclusion and next steps
  Organizing group

CO-ORGANIZERS: